<DOC>
	<DOCNO>NCT00116454</DOCNO>
	<brief_summary>The recurrence hepatocellular carcinoma ( HCC ) , two year curative treatment high , 40 % - 50 % . Recently , show intra-arterial radioactive lipiodol ( Lipiocis® ) could reduce recurrence cancer increase survival resection HCC develop cirrhosis B . The aim present trial investigate effect Lipiocis® prevent recurrence curative treatment HCC patient viral alcoholic hepatitis relate cirrhosis surgical percutaneous ablation .</brief_summary>
	<brief_title>Trial Hepatocellular Carcinoma Adjuvant Treatment Lipiocis</brief_title>
	<detailed_description>The usual therapeutic approach early hepatocellular carcinoma ( HCC ) partial hepatectomy percutaneous ethanol injection . However , therapeutic procedure suppress cirrhotic liver tissue represent major risk factor recurrence and/or occurrence second tumor liver . Recently , show intra-arterial radioactive lipiodol ( Lipiocis® ) could reduce recurrence cancer increase survival resection HCC develop cirrhosis B . The aim present randomize multicenter trial investigate effect iodine-131-labelled lipiodol ( 131I-lipiodol = Lipiocis® ) prevent recurrence curative treatment HCC ( hepatocellular carcinoma ) patient viral alcoholic hepatitis relate cirrhosis surgical percutaneous ablation . The period study 3 year include 1 year enrollment 2 year follow-up . Fifty patient receive one 2200 MBq dose Lipiocis 50 patient treat Lipiocis ( control group ) . The intra-arterial hepatic administration Lipiocis occur 11 12 week initial curative treatment . The inclusion criterion follow : 1 ) men woman , age 18 75 year old , cirrhosis chronic hepatitis associate C , B , delta infection alcool intake confirm liver biopsy 2 ) one two HCC nodule treat surgical percutaneous ablation ( ethanol , acetic acid 50 % radiofrequency ) . The efficacy initial curative treatment assess follow criterion : alpha-fetoprotein concentration 25ng/ml , progression size tumour demonstrate ultrasonography arterial hypervascularization CT scan imaging . The patient follow criterion exclude : co-infection HIV ( Human Immunodeficiency Virus ) associate CD count &lt; 200/mm3 viral charge &gt; 5000 HIV RNA copies/ml , document iodine intolerance , respiratory disease , decompensated cirrhosis ( Child-Pugh score equal 8 ) , bilirubin concentration 51µmol/l , portal hepatic vein thrombosis , extra-hepatic metastasis , excessive alcohol intake ( 50g per day ) , blood platelet count 50,000/mm3 , neutrophil count 1500/mm3 , creatininemia 120µmol/l , severe concurrent disease , previous treatment hepatocellular carcinoma woman pregnant breastfeeding . The main endpoint determine whether Lipiocis® treatment reduces percentage recurrence 50 % 20 % 24 month . The secondary end-points overall survival , survival without recurrence primary tumor , survival without new tumor , deterioration hepatocellular function side effect Lipiocis® treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hepatitis , Viral , Human</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Men woman , age 18 75 year old Cirrhosis chronic hepatitis associate C , B , delta infection alcool intake confirm liver biopsy One two HCC nodule treat surgical percutaneous ablation ( ethanol , acetic acid 50 % radiofrequency ) . The efficacy initial curative treatment assess follow criterion : alphafetoprotein concentration &lt; equal 25ng/ml , progression size tumour demonstrate ultrasonography arterial hypervascularization CT scan image HIV coinfection associate CD count &lt; 200/mm3 viral charge &gt; 5000 HIV RNA copies/ml Documented iodine intolerance Respiratory insufficiency Decompensated cirrhosis ( ChildPugh score 8 ) Bilirubin concentration 51 µmol/l Portal hepatic vein thrombosis Extrahepatic metastasis Excessive alcohol intake ( 50g per day ) Blood platelet count 50000/mm3 Neutrophil count 1500/mm3 Creatininemia 120µmol/l Myocardial infarction rhythm disorder Psychiatric disease hospitalization Previous treatment hepatocellular carcinoma Pregnant breastfeeding Treatment interferon and/or ribavirin 3 month inclusion Treatment tamoxifen somatostatin analog systemic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Viral Hepatitis , Alcoholic Hepatitis</keyword>
</DOC>